{"resourceType":"ValueSet","id":"detectedissue-category","meta":{"lastUpdated":"2016-03-31T08:01:25.570+11:00","profile":["http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-oid","valueUri":"urn:oid:2.16.840.1.113883.4.642.2.103"}],"url":"http://hl7.org/fhir/ValueSet/detectedissue-category","version":"1.4.0","name":"Detected Issue Category","status":"draft","experimental":true,"publisher":"FHIR Project team","contact":[{"telecom":[{"system":"other","value":"http://hl7.org/fhir","rank":1}]}],"description":"Kinds of issues or contraindications, such as \u0027drug-drug interaction\u0027, \u0027duplicate therapy\u0027, etc.","immutable":false,"extensible":false,"compose":{"include":[{"system":"http://hl7.org/fhir/v3/ActCode","filter":[{"property":"concept","op":"is-a","value":"_AdministrationDetectedIssueCode"}]},{"system":"http://hl7.org/fhir/v3/ActCode","filter":[{"property":"concept","op":"is-a","value":"_SupplyDetectedIssueCode"}]}]}}